U.S. flag

An official website of the United States government

NM_183235.3(RAB27A):c.121A>G (p.Thr41Ala) AND Griscelli syndrome type 2

Germline classification:
Conflicting interpretations of pathogenicity (2 submissions)
Last evaluated:
Apr 19, 2021
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001367530.11

Allele description [Variation Report for NM_183235.3(RAB27A):c.121A>G (p.Thr41Ala)]

NM_183235.3(RAB27A):c.121A>G (p.Thr41Ala)

Gene:
RAB27A:RAB27A, member RAS oncogene family [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
15q21.3
Genomic location:
Preferred name:
NM_183235.3(RAB27A):c.121A>G (p.Thr41Ala)
HGVS:
  • NC_000015.10:g.55234814T>C
  • NG_009103.1:g.59990A>G
  • NM_004580.5:c.121A>G
  • NM_183234.2:c.121A>G
  • NM_183235.3:c.121A>GMANE SELECT
  • NM_183236.3:c.121A>G
  • NP_004571.2:p.Thr41Ala
  • NP_899057.1:p.Thr41Ala
  • NP_899058.1:p.Thr41Ala
  • NP_899059.1:p.Thr41Ala
  • LRG_96:g.59990A>G
  • NC_000015.9:g.55527012T>C
Protein change:
T41A
Links:
dbSNP: rs1896186645
NCBI 1000 Genomes Browser:
rs1896186645
Molecular consequence:
  • NM_004580.5:c.121A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_183234.2:c.121A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_183235.3:c.121A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_183236.3:c.121A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Griscelli syndrome type 2 (GS2)
Synonyms:
Griscelli syndrome with hemophagocytic syndrome; Partial albinism and immunodeficiency syndrome
Identifiers:
MONDO: MONDO:0011872; MedGen: C1868679; Orphanet: 381; Orphanet: 79477; OMIM: 607624

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001563883Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely pathogenic
(Dec 10, 2020)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV003810447Revvity Omics, Revvity
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Apr 19, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001563883.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variant has been observed in individual(s) with hemophagocytic lymphohistiocytosis (Invitae). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with alanine at codon 41 of the RAB27A protein (p.Thr41Ala). The threonine residue is highly conserved and there is a small physicochemical difference between threonine and alanine. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAB27A protein function. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Revvity Omics, Revvity, SCV003810447.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024